178 related articles for article (PubMed ID: 18060862)
1. CD200: a putative therapeutic target in cancer.
Moreaux J; Veyrune JL; Reme T; De Vos J; Klein B
Biochem Biophys Res Commun; 2008 Feb; 366(1):117-22. PubMed ID: 18060862
[TBL] [Abstract][Full Text] [Related]
2. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias.
Wang W; Ji P; Steffen B; Metzger R; Schneider PM; Halfter H; Schrader M; Berdel WE; Serve H; Müller-Tidow C
Acta Biochim Biophys Sin (Shanghai); 2005 Mar; 37(3):173-80. PubMed ID: 15756419
[TBL] [Abstract][Full Text] [Related]
3. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
Koning N; Swaab DF; Hoek RM; Huitinga I
J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
[TBL] [Abstract][Full Text] [Related]
4. Ligation of CD200R by CD200 is not required for normal murine myelopoiesis.
Rijkers ES; de Ruiter T; Buitenhuis M; Veninga H; Hoek RM; Meyaard L
Eur J Haematol; 2007 Nov; 79(5):410-6. PubMed ID: 17803680
[TBL] [Abstract][Full Text] [Related]
5. Identification of an expressed truncated form of CD200, CD200tr, which is a physiologic antagonist of CD200-induced suppression.
Chen Z; Chen DX; Kai Y; Khatri I; Lamptey B; Gorczynski RM
Transplantation; 2008 Oct; 86(8):1116-24. PubMed ID: 18946351
[TBL] [Abstract][Full Text] [Related]
6. CD200R signaling in tumor tolerance and inflammation: A tricky balance.
Rygiel TP; Meyaard L
Curr Opin Immunol; 2012 Apr; 24(2):233-8. PubMed ID: 22264927
[TBL] [Abstract][Full Text] [Related]
7. CD70 as a therapeutic target in human malignancies.
Grewal IS
Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
[TBL] [Abstract][Full Text] [Related]
8. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.
Palumbo GA; Parrinello N; Fargione G; Cardillo K; Chiarenza A; Berretta S; Conticello C; Villari L; Di Raimondo F
Leuk Res; 2009 Sep; 33(9):1212-6. PubMed ID: 19230971
[TBL] [Abstract][Full Text] [Related]
9. Embryonic stem cell markers expression in cancers.
Schoenhals M; Kassambara A; De Vos J; Hose D; Moreaux J; Klein B
Biochem Biophys Res Commun; 2009 May; 383(2):157-62. PubMed ID: 19268426
[TBL] [Abstract][Full Text] [Related]
10. STEAP1 is overexpressed in cancers: a promising therapeutic target.
Moreaux J; Kassambara A; Hose D; Klein B
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
[TBL] [Abstract][Full Text] [Related]
11. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
12. CD200 is a new prognostic factor in multiple myeloma.
Moreaux J; Hose D; Reme T; Jourdan E; Hundemer M; Legouffe E; Moine P; Bourin P; Moos M; Corre J; Möhler T; De Vos J; Rossi JF; Goldschmidt H; Klein B
Blood; 2006 Dec; 108(13):4194-7. PubMed ID: 16946299
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma.
Yamano Y; Uzawa K; Shinozuka K; Fushimi K; Ishigami T; Nomura H; Ogawara K; Shiiba M; Yokoe H; Tanzawa H
Int J Oncol; 2008 May; 32(5):1001-9. PubMed ID: 18425326
[TBL] [Abstract][Full Text] [Related]
14. CD200, a "no danger" signal for hair follicles.
Rosenblum MD; Yancey KB; Olasz EB; Truitt RL
J Dermatol Sci; 2006 Mar; 41(3):165-74. PubMed ID: 16386879
[TBL] [Abstract][Full Text] [Related]
15. Drug transporters as targets for cancer chemotherapy.
Nakanishi T
Cancer Genomics Proteomics; 2007; 4(3):241-54. PubMed ID: 17878527
[TBL] [Abstract][Full Text] [Related]
16. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Huq A; Singh B; Meeker T; Mascarenhas D
Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
[TBL] [Abstract][Full Text] [Related]
17. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
Conticello C; Giuffrida R; Parrinello N; Buccheri S; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F
Leuk Res; 2013 Dec; 37(12):1616-21. PubMed ID: 24183830
[TBL] [Abstract][Full Text] [Related]
18. The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains.
Hatherley D; Barclay AN
Eur J Immunol; 2004 Jun; 34(6):1688-94. PubMed ID: 15162439
[TBL] [Abstract][Full Text] [Related]
19. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha.
Chen Z; Marsden PA; Gorczynski RM
Mol Immunol; 2009 Jun; 46(10):1951-63. PubMed ID: 19386363
[TBL] [Abstract][Full Text] [Related]
20. CD200 expression in plasma cell myeloma.
Olteanu H; Harrington AM; Hari P; Kroft SH
Br J Haematol; 2011 May; 153(3):408-11. PubMed ID: 21275968
[No Abstract] [Full Text] [Related]
[Next] [New Search]
